Monosaccharides are the simplest form of carbohydrates that are easily absorbed in intestine compared to the disaccharide, oligosaccharide and polysaccharide. CD BioGlyco has a professional carbohydrate-based glycomedicine development platform with multiple world-leading technologies to help customers comprehensively promote the development of monosaccharide-based glycomedicine.
Monosaccharides are carbohydrate molecules that cannot be broken down by hydrolysis into simpler (smaller) carbohydrate molecules. According to their chain length, monosaccharides fall into several categories, the more nutritionally important being the pentoses (5-carbon atom skeleton), e.g., ribose, and the hexoses (6-carbon atom skeleton), e.g., glucose.
Monosaccharides are important metabolic intermediates, essential components of various body fluids, and important biometric markers. Monosaccharides enter into numerous interactions with specific membrane transporters, intracellular enzymes, and carbohydrate receptors, which suggests avenues for important biomedical developments. The importance of monosaccharides in chemical biology is now well appreciated and as a result, much attention has been placed on the development of new biomedical applications for both monosaccharides and their derivatives.
Fig.1 Structures and symbols of common monosaccharides in N-glycans. (Chao, et al., 2020)
CD BioGlyco has a developed highly specialized platform and various systematic solutions for the development of monosaccharide-based glycomedicine. We offer services of isolation, purification, biological activity assay, and structural identification of monosaccharides. We also provide modification services, mainly including glycosylation, phosphorylation and sulfation. For example, glycosylation of hexose (e.g. glucose, mannose, and fructose) with proteins to diagnose diseases such as diabetes and Alzheimer's disease. Phosphorylated and sulfated monosaccharides for significantly improved post-ischemic cardiac function and inhibition of mammary tumor factors. Last but not least is the synthesis of amino sugars such as glucosamine for monitoring diabetes mellitus in medicine and deoxysaccharides, which express a range of extremely interesting biological activities that include antibiotic, antitumor, and antimalaria activities, as well as profound effects on cell-cell adhesion and cellular activation.
CD BioGlyco has a comprehensive glycomedicine development platform to help with customers' in-depth study of monosaccharide-based glycomedicine development. Our professional research teams provide customers with high-quality custom services according to their needs. If you are interested in our services, please contact us to obtain more information.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.